You have no items in your shopping cart.
Cart summary
Serpin A3 Protein, Human, Recombinant (His)
Catalog Number: orb1958329
| Catalog Number | orb1958329 |
|---|---|
| Category | Proteins |
| Description | SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation. |
| Tag | C-His |
| Purity | 98.00% |
| MW | 46.5 kDa (predicted); 45 kDa and 55-70 kDa (reducing condition, due to glycosylation) |
| UniProt ID | P01011 |
| Expression System | HEK293 Cells |
| Biological Origin | Human |
| Biological Activity | SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation. |
| Expression Region | A DNA sequence encoding the human SERPINA3 (NP_001076.2) (Met 1-Ala 423) was expressed, with a C-terminal polyhistidine tag. Predicted N terminal: Asn 26 |
| Storage | -20°C |
| Note | For research use only |
| Application notes | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| Expiration Date | 6 months from date of receipt. |
- Item 1 of 1
Human Serpin A3 Protein, His Tag [orb257833]
Unconjugated
95%
46.6 kDa
Human Serpin A3, His Tag (orb257833) is expressed from human 293 cells (HEK293). It contains AA His 24 - Ala 423 (Accession # AAH03559).
1 mg, 50 μg Human SERPINA3 protein [orb392453]
ELISA, MS, SDS-PAGE, WB
Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE.
Human cells
500 μg, 10 μg, 50 μgRecombinant Human Serpin A3/AACT Protein, His Tag [orb1551294]
> 97% by SDS-PAGE.
Recombinant Human Serpin A3/AACT Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Asn26-Ala423) of human Serpin A3/AACT (Accession #NP_001076.2) fused with a 6��His Tag at the C-terminus.
50 μg, 100 μg
